¼¿ï¾Æ»êº´¿ø Á¦ 9ȸ °£¼¾ÅÍ ½ÉÆ÷Áö¾ö : 2019-04-27±³À°ÀÏÀÚ : 2019-04-27
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø µ¿°ü6Ãþ ¼Ò°´ç
±³À°ÁÖÁ¦ :
Á¦ 9ȸ °£¼¾ÅÍ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ¼¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ¹ÚÁø¾Æ
¿¬¶ôó : 02-3010-1334
À̸ÞÀÏ :
pred1054@naver.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 09:30~09:50 Clinical implications of immunogenomics in hepatocellular carcinoma ½ÉÁÖÇö(¼¿ï¾Æ»êº´¿ø ¼Òȱ⳻°ú)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 09:50~10:15 Immunogenomics of hepatocellular carcinoma (TBD) Hidewaki Nakagawa(University of Tokyo)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 10:15~10:40 Biomarker and future of immunotherapy in HCC Stephen L. Chan(The Chinese University of Hong Kong)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 10:40~11:05 Combined immunotherapy and radiotherapy in treating HCC (TBD) Jason Chia-Hsien Cheng(National Taiwan University)
Åä·Ð 04-27 µ¿°ü6Ãþ ¼Ò°´ç 11:05~11:25 Q & A ()
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 13:00~13:20 How to determine optimal treatment for HCC : beyond conventional staging ±è¼Ò¿¬(¼¿ï¾Æ»êº´¿ø ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 13:20~13:40 Primary and secondary prevention of HCC in HBV-infected patients ÃÖÁ¾±â(¼¿ï¾Æ»êº´¿ø ¼Òȱ⳻°ú)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 13:40~14:05 Innovative surgical techniques (TBD) Kenneth Siu-Ho Chok(Kenneth Siu-Ho Chok)
Åä·Ð 04-27 µ¿°ü6Ãþ ¼Ò°´ç 14:05~14:20 Q & A ()
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 14:40~15:00 Transarterial embolotherapy ÃßÈñÈ£(¼¿ï¾Æ»êº´¿ø ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 15:00~15:20 Controlling the liberal liver: novel techniques in radiotherapy Á¤ÁøÈ«(¼¿ï¾Æ»êº´¿ø ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 04-27 µ¿°ü6Ãþ ¼Ò°´ç 15:20~15:40 Role of Nursing in the Management of HCC ¹ÚÁø¾Æ(¼¿ï¾Æ»êº´¿ø °£¼¾ÅÍ Àü´ã°£È£»ç)
Åä·Ð 04-27 µ¿°ü6Ãþ ¼Ò°´ç 15:40~15:55 Q & A ()